About
Products
Knolens
KnolScapes
Knolens
Knolens SLR
Knolens
KnolQuest
Knolens
Edge
Knolens
DataNexus
Platform
Solutions
KnolSights
Signup For Free
Serina Therapeutics Advances POZ-VMAT2i for Tardive Dyskinesia
Serina Therapeutics announced the advancement of SER-270 (POZ-VMAT2i), a novel, once-weekly injectable VMAT2 inhibitor, for treating tardive dyskinesi...
Copyright © 2025. All rights reserved
About
Terms of Service
Privacy Policy
Home/
KnloSights/
Clinical Trial Updates/
Serina Therapeutics Advances POZ-VMAT2i for Tardive Dyskinesia